Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study
B Baussart, C Villa, A Jouinot… - European Journal of …, 2021 - academic.oup.com
Objective Microprolactinomas are currently treated with dopamine agonists. Outcome
information on microprolactinoma patients treated by surgery is limited. This study reports …
information on microprolactinoma patients treated by surgery is limited. This study reports …
Molecular network basis of invasive pituitary adenoma: a review
Q Yang, X Li - Frontiers in endocrinology, 2019 - frontiersin.org
Cases with pituitary adenoma comprise 10–25% of intracranial neoplasm, being the third
most common intracranial tumor, most of the adenomas are considered to be benign. About …
most common intracranial tumor, most of the adenomas are considered to be benign. About …
Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions
J Trouillas, ML Jaffrain-Rea, A Vasiljevic… - Reviews in Endocrine …, 2020 - Springer
Pituitary adenohypophyseal tumors are considered as benign and termed “adenomas”.
However, many tumors are invasive and a proportion of these exhibit an “aggressive …
However, many tumors are invasive and a proportion of these exhibit an “aggressive …
Immune landscape of pituitary tumors reveals association between macrophages and gonadotroph tumor invasion
M Principe, M Chanal, MD Ilie, A Ziverec… - The Journal of …, 2020 - academic.oup.com
Abstract Purpose Pituitary neuroendocrine tumors (PitNETs) are frequent intracranial
neoplasms that present heterogenic characteristics. Little is known about the immune cell …
neoplasms that present heterogenic characteristics. Little is known about the immune cell …
Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth
E Delgrange, A Vasiljevic, A Wierinckx… - European journal of …, 2015 - academic.oup.com
Context A sex difference in the progression of prolactin (PRL) tumors has been disputed for
years. Objective To compare tumor characteristics and postoperative clinical course …
years. Objective To compare tumor characteristics and postoperative clinical course …
Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies
G Raverot, E Jouanneau… - European journal of …, 2014 - academic.oup.com
Pituitary tumours, the most frequent intracranial tumour, are historically considered benign.
However, various pieces of clinical evidence and recent advances in pathological and …
However, various pieces of clinical evidence and recent advances in pathological and …
Clinical, pathological, and molecular factors of aggressiveness in lactotroph tumours
J Trouillas, E Delgrange, A Wierinckx, A Vasiljevic… - …, 2019 - karger.com
The behaviour of lactotroph tumours varies between benign tumours, those cured by
treatment, and that of aggressive tumours, and carcinomas with metastasis. Identification of …
treatment, and that of aggressive tumours, and carcinomas with metastasis. Identification of …
The risks of overlooking the diagnosis of secreting pituitary adenomas
T Brue, F Castinetti - Orphanet journal of rare diseases, 2016 - Springer
Secreting pituitary adenomas that cause acromegaly and Cushing's disease, as well as
prolactinomas and thyrotroph adenomas, are uncommon, usually benign, slow-growing …
prolactinomas and thyrotroph adenomas, are uncommon, usually benign, slow-growing …
Invasive adenoma and pituitary carcinoma: a SEER database analysis
Invasive pituitary adenomas and pituitary carcinomas are clinically indistinguishable until
identification of metastases. Optimal management and survival outcomes for both are not …
identification of metastases. Optimal management and survival outcomes for both are not …
Surgery for prolactinomas: a better choice?
J Honegger, I Nasi-Kordhishti, N Aboutaha, S Giese - Pituitary, 2020 - Springer
Purpose Renewed interest in transsphenoidal surgery (TSS) as a therapeutic option for
prolactinomas has emerged. Methods Based on contemporary literature and own …
prolactinomas has emerged. Methods Based on contemporary literature and own …